Free press releases distribution network?

More news: Research
Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



High Incidence and Inadequate Treatments Boost Prospects of HIV, Chagas, Dengue & Influenza H1N1 Therapeutics in Latin America Finds Frost & Sullivan - Pharmaceutical companies work with governments in the region to increase disease awareness and access to treatment - LifeSciences.Frost.com
High Incidence and Inadequate Treatments Boost Prospects of HIV, Chagas, Dengue & Influenza H1N1 Therapeutics in Latin America Finds Frost & Sullivan

 

PRZOOM - /newswire/ - Buenos Aires, Argentina, 2014/03/13 - Pharmaceutical companies work with governments in the region to increase disease awareness and access to treatment - LifeSciences.Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The high incidence of, human immunodeficiency virus (HIV), Chagas, dengue and influenza H1N1, as well as the unavailability of adequate treatments for these infectious diseases spell opportunities for pharmaceutical companies across Latin America to develop new, improved diagnosis and treatment methods.

New analysis from Frost & Sullivan (lifesciences.frost.com), A Product and Pipeline Analysis of the Latin American HIV, Chagas, Dengue, and Influenza H1N1 Therapeutics Markets, finds that Chagas ranks the highest in terms of relative prevalence, and the 50 percent efficacy rate of current treatments means that this is a market to be tapped and developed. HIV has the second-highest incidence rate, followed by dengue and influenza H1N1.

"Pharmaceutical companies in Latin America currently offer numerous generic drugs for the treatment of HIV at reduced prices owing to intense competition in the market," stated Frost & Sullivan Healthcare Industry Analyst Lucila Rocca. "Even though these drugs assure a longer and better life for patients, they do not cure the disease, thus leaving considerable room for more effective therapies."


Although there are presently no effective therapies available for the treatment of dengue, Sanofi-Pasteur will introduce a vaccine by 2016, which will prevent serotypes I, III and IV of the virus. As far as treatment of Chagas is concerned, a pro-drug of ravuconazole and posaconazole is expected to obtain regulatory approval in the next five years.

"Pharmaceutical companies should assist governments across Latin America to control the spread of HIV, Chagas, dengue, and influenza H1N1 mostly resulting from poverty and poor housing by educating the population on the prevalence and causes of these conditions," noted Rocca. "They should also collaborate to improve diagnostic methods and the patients’ access to the system in Latin America."

Overall, the outlook for pharmaceutical companies is promising especially in view of the aging population in Latin America. However, it will be important for generic pharmaceutical companies to continue to offer products at lower prices as governments across the region, which already reimburse 100 percent of the cost of medication to patients infected with HIV and influenza H1N1, purchase large amounts of the lowest-priced medication and vaccines in the market.

If you are interested in more information on this research, please send an email to Francesca Valente, Corporate Communications, at francesca.valente[.]frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

A Product and Pipeline Analysis of the Latin American HIV, Chagas, Dengue, and Influenza H1N1 Therapeutics Markets is part of the Life Sciences Growth Partnership Service program. Frost & Sullivan’s related research services include: Trends, Opportunities, and Challenges for the Latin American Diabetes Therapeutics Market; China’s 2013 Life Sciences Industry Outlook and Regulatory Review; Competitive Analysis of the Global Opioid Therapeutics Market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion | Join Us: Join our community | Subscribe: Newsletter on "the next big thing"| Register: Gain access to visionary innovation

A Product and Pipeline Analysis of the Latin American HIV, Chagas, Dengue, and Influenza H1N1 Therapeutics Markets / ND3B-52

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Research articles,
CATCH Visitors via Your Competitors Announcements!


High Incidence and Inadequate Treatments Boost Prospects of HIV, Chagas, Dengue & Influenza H1N1 Therapeutics in Latin America Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
H1N1 Therapeutics | Frost & Sullivan
Contact: Francesca Valente - Frost.com 
+54 11 4777 5300 francesca.valente[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Research via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Research Most Recent Related Press Releases:

DSM-Niaga Ready for Commercial Scale Production of 100%-recyclable Carpets
DSM Dyneema Introduces Whole New Level of Cut Protection with Black Dyneema® Diamond Technology
DSM Presents Sustainable and Healthy Dairy Solutions At FoodTech 2016
Frost & Sullivan Highlights GENEWIZ's Commitment to Providing Cutting-edge Services in the Life Science Research Services Market
DSM to Present its Latest Advances in Skin Biochemistry At IFSCC Conference
DSM Launches ForTii® Ace Next Generation High Performance Polyamides
DSM Launches New Cultures to Reduce Cheese Ripening Time
DSM Launches New 3C Technology to Reinvigorate Omega-3 Supplements Category
DSM to Highlight its Health and Indulgence Solutions for Baked Goods At IBIE
DSM Welcomes EU Novel Foods Approval for Heart Health Antioxidant

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  Triggr & Bloom

Visit  JobsWare.com

Visit  BizJobs.com







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today